Halozyme Therapeutics | HALO - Equity Capital And Reserves


Halozyme Therapeutics reported $219.64M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 1.25B 20.68M Mar/2026
Agios Pharmaceuticals USD 1.11B 84M Mar/2026
Alnylam Pharmaceuticals USD 1.08B 286.2M Mar/2026
Amarin USD 449.41M 9.87M Mar/2026
Amgen USD 9.19B 532M Mar/2026
Baxter International USD 6.04B 86M Mar/2026
Cara Therapeutics USD 20.95M 6.92M Dec/2025
Cytokinetics USD -826.57M 166.94M Mar/2026
DBV Technologies USD 168.77M 115.92M Dec/2025
Eli Lilly USD 31.2B 4.66B Mar/2026
Esperion Therapeutics USD -307.93M 5.97M Mar/2026
Halozyme Therapeutics USD 219.64M 170.82M Mar/2026
Intrexon USD 43.17M 75.33M Jun/2024
Ionis Pharmaceuticals USD 491.41M 2.32M Mar/2026
MannKind USD -59.2M 8.17M Mar/2026
Minerva Neurosciences USD -140.75M 106.17M Dec/2025
Nektar Therapeutics USD 89.83M 4.75M Dec/2025
Pfizer USD 90.1B 3.63B Mar/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
United Therapeutics USD 5.9B 1.2B Mar/2026
Vanda Pharmaceuticals USD 327.19M 138.81M Dec/2025